Pfizer Reports Third-Quarter 2023 Results
Pfizer Reports Third-Quarter 2023 Results
– Revenues for Pfizer’s Non-COVID Products Grew 10% OperationallyNEW YORK, Tuesday, October 31, 2023 — Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2023.
纽约，2023 年 10 月 31 日，星期二——辉瑞公司（纽约证券交易所代码：PFE）公布了 2023 年第三季度的财务业绩。
HIGHLIGHTS
亮点
▪ Third-Quarter 2023 Revenues of $13.2 Billion
▪ 2023 年第三季度收入为 132 亿美元
– Expected Decline in Paxlovid and Comirnaty Revenues Drove 41% Operational Decrease in ThirdQuarter 2023 Revenues
— Paxlovid和Comirnaty收入的预期下降使2023年第三季度收入的运营收入下降了41％
– Revenues for Pfizer’s Non-COVID Products Grew 10% Operationally
—辉瑞非COVID产品的收入在运营中增长了10％
▪ Third-Quarter 2023 Reported Diluted Loss Per Share (LPS) of $(0.42) and Adjusted Diluted LPS of $(0.17), Significantly Impacted by $5.6 Billion of Non-Cash Inventory Write-Offs and Other Charges, Which Unfavorably Impacted Reported and Adjusted Diluted LPS by $0.84
▪ 2023年第三季度公布的摊薄后每股亏损（LPS）为0.42美元，调整后的摊薄后每股亏损为0.17美元，受到56亿美元非现金库存注销和其他费用的重大影响，这对报告和调整后的摊薄后每股收益产生了0.84美元的不利影响
▪ Reaffirms Full-Year 2023 Guidance Provided on October 13, 2023, of Revenues of $58.0 to $61.0 Billion and Adjusted Diluted EPS of $1.45 to $1.65, and Provides All Guidance Components
▪ 重申2023年10月13日提供的2023年全年指引，即收入为580亿美元至610亿美元，调整后的摊薄后每股收益为1.45美元至1.65美元，并提供了所有指导要素
▪ Reaffirms Full-Year 2023 Non-COVID Operational Revenue Growth Expectation of 6% to 8% vs. 2022
▪ 重申 2023 年全年非新冠肺炎运营收入增长预期与 2022 年相比为 6% 至 8%
▪ Successful Execution of New Product and Indication Launches, including Abrysvo (Older Adult) and Prevnar 20 (Pediatric), and In-Line Product Growth Contribute to Strong Non-COVID Operational Revenue Growth
▪ 成功实施新产品和适应症的发布，包括Abrysvo（老年人）和Prevnar 20（儿科），以及在线产品的增长有助于非COVID运营收入的强劲增长
▪ Launched Enterprise-Wide Cost Realignment Program Expected to Deliver Annual Net Cost Savings of at Least $3.5 Billion, of Which Approximately $1.0 Billion is Expected to be Realized in 2023 and at Least an Additional $2.5 Billion is Expected to be Realized in 2024 (Compared to Midpoint of SI&A and R&D Expense Guidance Provided on August 1, 2023)
▪ 启动全企业成本调整计划，预计每年可节省至少35亿美元的净成本，其中约10亿美元预计将在2023年实现，另外至少25亿美元预计将在2024年实现（与2023年8月1日提供的SI&A和研发费用指导中点相比）
2023 FINANCIAL GUIDANCE
2023 年财务指导
Pfizer reaffirms its full-year 2023 guidance for Revenues, Adjusted diluted EPS and Effective Tax Rate on Adjusted Income provided on October 13, 2023, which is presented below. This guidance incorporates the impacts of certain one-time items, noted below.
辉瑞重申其于2023年10月13日提供的2023年全年收入、调整后摊薄每股收益和调整后所得有效税率指引，如下所示。该指南纳入了某些一次性项目的影响，如下所示。
